- Home
- BLCO vs MRUS Comparison
BLCO vs MRUS Comparison
Compare BLCO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLCO
- MRUS
- Stock Information
- Founded
- BLCO 1853
- MRUS 2003
- Country
- BLCO Canada
- MRUS Netherlands
- Employees
- BLCO N/A
- MRUS 260
- Industry
- BLCO Ophthalmic Goods
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BLCO Health Care
- MRUS Health Care
- Exchange
- BLCO Nasdaq
- MRUS Nasdaq
- Market Cap
- BLCO 4.4B
- MRUS 4.1B
- IPO Year
- BLCO 2022
- MRUS 2016
- Fundamental
- Price
- BLCO $11.70
- MRUS $53.11
- Analyst Decision
- BLCO Hold
- MRUS Strong Buy
- Analyst Count
- BLCO 13
- MRUS 12
- Target Price
- BLCO $15.63
- MRUS $87.92
- AVG Volume (30 Days)
- BLCO 578.9K
- MRUS 2.0M
- Earning Date
- BLCO 07-30-2025
- MRUS 07-31-2025
- Dividend Yield
- BLCO N/A
- MRUS N/A
- EPS Growth
- BLCO N/A
- MRUS N/A
- EPS
- BLCO N/A
- MRUS N/A
- Revenue
- BLCO $4,829,000,000.00
- MRUS $54,732,000.00
- Revenue This Year
- BLCO $6.97
- MRUS $75.57
- Revenue Next Year
- BLCO $5.48
- MRUS $31.84
- P/E Ratio
- BLCO N/A
- MRUS N/A
- Revenue Growth
- BLCO 11.94
- MRUS 42.77
- 52 Week Low
- BLCO $10.45
- MRUS $33.19
- 52 Week High
- BLCO $21.69
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- BLCO 45.65
- MRUS 53.18
- Support Level
- BLCO $11.44
- MRUS $52.41
- Resistance Level
- BLCO $12.70
- MRUS $54.59
- Average True Range (ATR)
- BLCO 0.36
- MRUS 2.15
- MACD
- BLCO 0.01
- MRUS -0.77
- Stochastic Oscillator
- BLCO 30.07
- MRUS 7.62
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.